A new, free-of-charge webinar in collaboration with the AAAS/Science magazine is available on demand since July 9th.
This webinar broadcasted on July, 7th discusses how the standard model for developing new medicines is often not profitable enough for pharmaceutical companies to produce therapeutics for the thousands of rare diseases known to exist. In the past, pharmaceuticals designed for common diseases have been repurposed for patients with rare diseases. However, that is all changing: new drug design methodologies allow us to contemplate designer medicines for very small groups of patients or even individuals.
More information and webinar available here.
